Comparing a potential biosimilar to Keytruda for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if a new drug, MB12, works as well as Keytruda for people with advanced non-small cell lung cancer who haven't had treatment yet. It aims to offer a more affordable option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced non-small cell lung cancer (stage IV) that has not spread to the brain and doesn't have certain gene changes (EGFR or ALK).
- You have not had any previous treatment for cancer that has spread.
- You have at least one tumor that can be measured on a scan.
- Your cancer cells have a known level of PD-L1 protein.
- You are in generally good health (able to do daily activities without help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a new drug called HLX17 works as well as the approved drug Keytruda for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see which one better controls the cancer.
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
This trial tests a new drug combination for people with a type of lung cancer that has spread or cannot be removed by surgery. It compares the new combination to the current standard treatment to see which works better.
This Phase 3 trial compares MB12 with Keytruda (both cancer medicines) for people with newly diagnosed stage IV non-squamous non-small-cell lung cancer. It looks at whether MB12 can work as well or better than Keytruda, and compares safety and immune responses.
This trial compares an experimental drug called Pumitamig with the approved immunotherapy drug Pembrolizumab (Keytruda) as the first treatment for advanced lung cancer that has high PD-L1 levels. The goal is to see which drug works better and has fewer side effects.
Hear when a new Non-squamous Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.